Retatrutide and your heart: what TRIUMPH-3 showed in patients with cardiovascular disease

TL;DR

• TRIUMPH-3 posted 21.6% and 22.6% weight reduction at 80 weeks in its two higher-dose arms (versus 3.2% on placebo) in 1,949 adults with a BMI of 35 or more and established cardiovascular disease, alongside improvements in triglycerides, blood pressure and inflammatory markers.
• TRIUMPH-2, in 1,152 adults with obesity and type 2 diabetes, reached up to 20.8% (versus 4.0% on placebo) plus up to 1.6 points of HbA1c reduction - both trials met their primary endpoints, announced together 23 July 2026, and both compared retatrutide with placebo only.
• A weight result in heart patients is not a heart result. TRIUMPH-3 was not a dedicated cardiovascular-outcomes trial: it was designed and powered as a weight-loss and safety study in people who already have heart disease.
• The cardiovascular-event analyses rested on low event counts and were not statistically significant, with confidence intervals spanning both benefit and harm, so a heart benefit is neither shown nor ruled out: it stays unestablished until the dedicated outcomes trial reports.
• The lower ceiling here is expected - cardiac cohorts are older and more medically complex than the pivotal obesity trial, which reported 28.3% under the same efficacy estimand (25.0% under the treatment-regimen estimand).
• Retatrutide is investigational and approved in no market, with a Biologics License Application planned for Q1 2027 and full safety data still pending publication.

Educational content, not medical advice. Retatrutide is investigational and not FDA-approved. No doses or protocols appear; treatment decisions belong with your physician.

Updated October 2026 (26 Oct): re-verified against Lilly's 23 July 2026 release. Adds TRIUMPH-3's second higher-dose arm (21.6%) and its BMI 35+ entry criterion, TRIUMPH-2's full dose-arm range and participant count, and states plainly that a weight endpoint in a cardiovascular population is not a cardiovascular outcomes result. Status re-checked: still investigational, BLA still planned for Q1 2027, not filed. Replaces a supply-verification CTA with a plain status link and a bloodwork-first recommendation.

Updated October 2026: corrects the TRIUMPH-1 estimand labels against Lilly's release: 28.3% (versus 2.2% placebo) is the efficacy estimand, 25.0% (versus 3.9% placebo) is the treatment-regimen estimand, and 30.3% is a separate 104-week extension in 532 participants with BMI of 35 or more; adds placebo figures for TRIUMPH-2 and TRIUMPH-3.

Updated September 2026: adds the TRIUMPH-3 participant count (1,949) and the triglyceride and inflammatory-marker improvements reported alongside blood pressure, replaces the blended "~30%" reading of the pivotal obesity trial with the reported estimand figures, and restates the planned filing as a Biologics License Application in Q1 2027 with a realistic approval window of late 2027 to 2028.

---

The retatrutide story has been the efficacy story in the weight-loss race, and the July 2026 readouts extend it into the population that matters most for hard outcomes: people who already have cardiovascular disease. That's a meaningful step - but it's important to separate what the trials actually showed (large weight loss and favorable risk-factor changes in a high-risk group) from what people will assume they showed (that retatrutide "protects the heart"). The first is supported. The second is not yet established.

What TRIUMPH-2 and TRIUMPH-3 tested

The two trials extended retatrutide's Phase 3 program (TRIUMPH) into harder populations than the original pivotal obesity trial:

• TRIUMPH-2 enrolled 1,152 adults with obesity or overweight and type 2 diabetes, testing weight loss and glycemic control.
• TRIUMPH-3 enrolled 1,949 adults with a BMI of 35 or more and established cardiovascular disease (type 2 diabetes was allowed) - the group at highest baseline risk, and the one where a weight-loss drug's safety and risk-factor effects matter most.

Both are once-weekly injectable retatrutide, a triple agonist acting on the GIP, GLP-1 and glucagon receptors - one more target than tirzepatide's dual mechanism. Both trials met their primary endpoints.

The headline numbers

The weight-loss results held up in these tougher populations, if slightly below the pivotal obesity trial's ceiling:

Two notes on reading that table. The pivotal trial carries two figures for the same top dose arm because it is analysed under two estimands: 28.3% under the efficacy estimand, the estimated effect had all randomised participants stayed on the study drug, and 25.0% under the treatment-regimen estimand, the average effect regardless of adherence, counting people who stopped treatment. The 30.3% figure sometimes quoted is neither: it comes from a separate 104-week extension in 532 participants with a baseline BMI of 35 or more. The TRIUMPH-2 and TRIUMPH-3 figures above are efficacy-estimand results, so 28.3% is the like-for-like benchmark against which to read the CVD cohort.

The lower ceilings in the T2D and CVD populations are expected - diabetes tends to blunt weight-loss response, and cardiac populations are older and more medically complex. Alongside weight loss, TRIUMPH-3 reported improvements in triglycerides, blood pressure and inflammatory markers, and TRIUMPH-2 reported up to 1.6 percentage points of HbA1c reduction. Those risk-factor moves are exactly what you'd hope to see, and they're clinically relevant on their own - though improving a marker is not the same as preventing an event, which is the distinction the rest of this page turns on.

Why a triple agonist might matter for the heart

The mechanistic case is reasonable. Weight loss of this magnitude improves nearly every cardiometabolic risk factor - blood pressure, glycemia, lipids, systemic inflammation - and the GLP-1 class already has proven cardiovascular-outcome benefits (semaglutide's SELECT trial being the landmark). Adding a glucagon-receptor arm may enhance energy expenditure and hepatic-fat reduction on top of that. So there's a plausible path by which retatrutide could eventually show a cardiovascular-outcomes benefit. For the broader mechanism, see how retatrutide's evidence stacks up and tirzepatide vs retatrutide.

But plausibility is not proof, which is the crucial caveat.

The cardiovascular-event data - read honestly

This is where the interpretation has to be disciplined. TRIUMPH-3 was designed and powered as a weight-loss and safety trial in a CVD population, not as a dedicated cardiovascular-outcomes trial. The event analyses reflect that: the composite cardiovascular-event estimates were based on low event counts and did not reach statistical significance, with wide confidence intervals spanning both benefit and harm. In practical terms, the trial shows retatrutide can produce large weight loss and better risk factors in cardiac patients without an obvious cardiovascular safety alarm - but it does not demonstrate that retatrutide prevents heart attacks or strokes. That claim would require a large, dedicated, event-powered outcomes trial, which is a different study.

Put simply: TRIUMPH-3 measured weight in people with heart disease. Its main result is a weight result. A cardiovascular outcomes result counts heart attacks, strokes and cardiovascular deaths in enough people, for long enough, to tell whether the drug changes them. Retatrutide's dedicated outcomes trial is still running, so that question is open, not answered either way.

Coverage of the readout also flagged that full safety data are still to come with formal publication and regulatory review. Until that fuller dataset is public, the responsible position is to treat the topline as encouraging on efficacy and risk factors, and unproven on hard cardiovascular outcomes.

Where retatrutide sits versus approved options today

The honest status: retatrutide is not approved anywhere as of 26 October 2026. Lilly says it is completing the manufacturing and quality package for a Biologics License Application, planned for Q1 2027 and not yet submitted - the biologics pathway, not a New Drug Application, and not the end-2026 filing earlier coverage assumed. A filing opens a review rather than concluding one, so on a realistic reading an approval would sit in late 2027 to 2028 at the earliest, with real-world availability later again. Today's approved and available options remain tirzepatide and semaglutide (and, as pills, oral semaglutide and orforglipron, approved by the FDA as Foundayo in April 2026) - retatrutide is the higher-ceiling candidate still in the regulatory pipeline. The wider landscape is mapped in new weight-loss drugs 2026–2027.

What this means for someone weighing options now

Three practical takeaways. First, retatrutide's data is genuinely strong, but it is not something you can be prescribed yet through legitimate channels - anyone offering "retatrutide" today is operating outside an approved supply, with the sourcing and identity risks that implies. Second, the risk-factor benefits (weight, blood pressure, glucose) are real and are largely a function of the weight loss itself - which the approved drugs also deliver. Third, none of this changes the fundamentals that determine whether any GLP-1-class drug works long-term: resistance training and protein to protect muscle, and a plan for maintenance rather than a plateau. The drug is not the protocol.

Frequently asked questions

Is retatrutide approved? No. As of 26 October 2026 it is investigational, and the application has not yet been submitted. Lilly has stated a Biologics License Application is planned for Q1 2027 - a biologics filing, not an NDA - so approval, if it comes, realistically sits in late 2027 to 2028 at the earliest.

Is retatrutide better for the heart than tirzepatide? It's too early to say. TRIUMPH-3 showed large weight loss and improved risk factors in patients with cardiovascular disease, but its cardiovascular-event analyses were underpowered and not statistically significant. A head-to-head cardiovascular-outcomes comparison doesn't exist.

What weight loss did TRIUMPH-3 show? 21.6% and 22.6% at 80 weeks in its two higher-dose arms (versus 3.2% on placebo) in 1,949 adults with a BMI of 35 or more and established cardiovascular disease, with improvements in triglycerides, blood pressure and inflammatory markers alongside it - below the 28.3% reported in the pivotal obesity trial (both efficacy-estimand figures), which is expected in a higher-risk, more medically complex population.

Was there a safety signal? The cardiovascular-event data were based on low event counts and were not statistically significant, and full safety data are still to be published and reviewed. The topline did not report an obvious cardiovascular safety alarm, but the complete dataset should be read before drawing firm conclusions.

Related reading

• How retatrutide's evidence stacks up · Tirzepatide vs retatrutide · New weight-loss drugs 2026–2027 · Retatrutide and knee pain: TRIUMPH-4 · GLP-1s beyond weight: the joint question · Protecting muscle on a GLP-1
• Part of The Complete Guide to GLP-1s

---

Where Vivre Labs fits

Vivre Labs keeps a retatrutide page that sets out its status: investigational, not approved in any market, with a US filing planned for Q1 2027. If heart health and weight are both on your mind, we recommend starting with baseline bloodwork, including lipids, blood sugar and inflammation markers, so you and your own doctor know where you stand.

---

Educational content, not medical advice. Retatrutide is investigational and not FDA-approved; trial figures are topline and subject to full publication and regulatory review. TRIUMPH-3 was not a dedicated cardiovascular-outcomes trial and does not establish a cardiovascular-event benefit. Treatment decisions belong with a qualified clinician. Claims for the Malaysian market are subject to MAB requirements.

References

• Eli Lilly investor release (23 July 2026), "Lilly's triple agonist retatrutide successful in two additional Phase 3 obesity trials" (investor.lilly.com; also HCPLive): retatrutide met primary endpoints in TRIUMPH-2 (n=1,152, obesity/overweight with type 2 diabetes) and TRIUMPH-3 (n=1,949, BMI 35+ with established cardiovascular disease), both 80 weeks and placebo-controlled; weight reduction 12.7% / 19.1% / 20.8% across dose arms versus 4.0% placebo (T2D; HbA1c 1.4 to 1.6 points versus 0.2) and 21.6% and 22.6% in the two higher-dose arms versus 3.2% placebo (CVD), efficacy estimand; TRIUMPH-3 improvements in triglycerides, blood pressure and inflammatory markers; Biologics License Application planned Q1 2027. · Cardiovascular-event composites (MACE) based on low event counts, not statistically significant (wide confidence intervals); full safety data pending publication. · TRIUMPH-1 pivotal obesity trial (n=2,339, topline 21 May 2026): top dose arm 28.3% versus 2.2% placebo at 80 weeks under the efficacy estimand, and 25.0% versus 3.9% placebo under the treatment-regimen estimand, 45.3% reaching ≥30% reduction; 30.3% in a pre-specified 104-week extension in 532 participants with baseline BMI ≥35 (Eli Lilly investor release, 21 May 2026); all three dose arms met primary and key secondary endpoints. · Class context: GLP-1 cardiovascular-outcomes benefit established for semaglutide (SELECT). · Reporting: Eli Lilly / PR Newswire, BioSpace, Endocrinology Advisor, Pharmaceutical Executive (July 2026).